ArticleThe ocular surface2016
Superior Limbic Keratoconjunctivitis-like Inflammation in Patients with Chronic Graft-Versus-Host Disease.
Article in The ocular surface, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Autologous serum eye drops in dry eye disease: Preferred practice pattern guidelines.Indian journal of ophthalmology · 2023Guideline
- Ocular Manifestations and Management of Graft-versus-Host Disease: A Comprehensive Review.Ophthalmic research · 2026Review
- Clinical Outcomes of Different Surgical Techniques in Limbal Stem Cell Deficiency.Turkish journal of ophthalmology · 2025Article
- AI-Based Estimate of the Regional Effect of Orthokeratology Lenses on Tear Film Quality.Bioengineering (Basel, Switzerland) · 2025Article
- A novel tissue-engineered corneal epithelium based on ultra-thin amniotic membrane and mesenchymal stem cells.Scientific reports · 2024Article
- Ophthalmic Manifestations in Patients with Blood Malignancies.Hematology reports · 2024Review
- Diagnostic approach to limbal stem cell deficiency.Frontiers in ophthalmology · 2024Review
- The ocular graft-versus-host disease: the path from current knowledge to future managements.Eye (London, England) · 2023Review
- Recent advances in ocular graft-versus-host disease.Frontiers in immunology · 2023Review
- Profile of biological characterizations and clinical application of corneal stem/progenitor cells.World journal of stem cells · 2022Review
- A plethora of ocular surface manifestations in a multidisciplinary ocular graft-versus-host disease unit.Scientific reports · 2022Article
- Recharacterization of superior limbic keratoconjunctivitis via a subdividing grading method in 236 Chinese patients.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Article
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report.Transplantation and cellular therapy · 2021Article
- Update on ocular graft-versus-host disease.Indian journal of ophthalmology · 2021Review
- Meibomian Gland Dysfunction in Ocular Graft vs. Host Disease: A Need for Pre-Clinical Models and Deeper InsightsInternational journal of molecular sciences · 2021Review
- Nanotechnology in regenerative ophthalmology.Advanced drug delivery reviews · 2019Review
- Ocular surface system alterations in ocular graft-versus-host disease: all the pieces of the complex puzzle.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2019Review
- Neutrophil extracellular traps (NETs) contribute to pathological changes of ocular graft-vs.-host disease (oGVHD) dry eye: Implications for novel biomarkers and therapeutic strategies.The ocular surface · 2019Article
- The diagnosis of limbal stem cell deficiency.The ocular surface · 2018Review
- Limbal and corneal epithelial homeostasis.Current opinion in ophthalmology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
purposeDescribe the presentation and management of superior limbic keratoconjunctivitis (SLK)-like inflammation and secondary limbal stem cell dysfunction in the setting of ocular chronic graft-versus-host disease (cGVHD).
methodsRetrospective observational case series in a multicenter clinical practice. Participants were 13 patients (26 eyes) with ocular cGVHD and SLK-like inflammation presenting to the University of Illinois at Chicago and BostonSight® between January 1, 2009 and July 1, 2013.
main outcome measures1) Reversal or worsening of SLK, and 2) development of limbal stem cell dysfunction.
resultsAll eyes showed evidence of SLK-like inflammation and superior limbal stem cell dysfunction manifested by conjunctival injection and superior conjunctival and corneal staining. In addition to aggressive lubrication, management strategies for SLK included topical steroids (20/26), punctal occlusion (18/26), topical cyclosporine (24/26), autologous serum tears (12/26), therapeutic soft contact lens (13/26 eyes) and scleral lenses (4/26 eyes). SLK and limbal stem cell dysfunction were reversed in 23/26 eyes. Three eyes of two patients with long-standing disease demonstrated frank limbal stem cell deficiency (LSCD) and corneal pannus, with one patient requiring multiple reconstructive surgical procedures.
conclusionsSLK-like inflammation is an under-recognized condition in patients with severe dry eyes secondary to ocular cGVHD. Untreated SLK can potentially lead to permanent LSCD over time. Early recognition and management of SLK in ocular cGVHD can improve vision, reverse signs, and may prevent these long-term consequences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.